Passar para o conteúdo principal

Transcranial direct current stimulation of 3 cortical targets is no more effective than placebo as treatment for fibromyalgia: a double-blind sham-controlled clinical trial

Transcranial direct current stimulation of 3 cortical targets is no more effective than placebo as treatment for fibromyalgia: a double-blind sham-controlled clinical trial

Samartin-Veiga, Noelia

;

Pidal-Miranda, Marina

; González-Villar, Alberto J.;

Bradley, Claire

;

Garcia-Larrea, Luis

;

O'Brien, Anthony T.

;

Carrillo-de-la-Peña, María T.

| International Association for the Study of Pain | 2022 | DOI

Artigo de Jornal

Transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) and the dorsolateral prefrontal cortex seem to improve pain and other symptoms of fibromyalgia (FM), although the evidence on the effectiveness of tDCS and the optimal stimulation target is not robust enough. Our main objective was to establish the optimal area of stimulation, comparing the 2 classical targets and a novel pain-related area, the operculo-insular cortex, in a sham-controlled trial. Using a double-blind design, we randomly assigned 130 women with FM to 4 treatment groups (M1, dorsolateral prefrontal cortex, operculo-insular cortex, and sham), each receiving fifteen 20-minute sessions of 2 mA anodal tDCS over the left hemisphere. Our primary outcome was pain intensity. The secondary outcomes were the other core symptoms of FM (fatigue, mood, cognitive and sleep disorders, and hyperalgesia measured by the pressure pain threshold). We performed the assessment at 3 time points (before, immediately after treatment, and at 6 months follow-up). The linear mixed-model analysis of variances showed significant treatment effects across time for clinical pain and for fatigue, cognitive and sleep disturbances, and experimental pain, irrespective of the group. In mood, the 3 active tDCS groups showed a significantly larger improvement in anxiety and depression than sham. Our findings provide evidence of a placebo effect, support the use of tDCS for the treatment of affective symptoms, and challenge the effectiveness of tDCS as treatment of FM.
This study has been funded by the Spanish
Government (Ministerio de Economía y Competitividad; ref
PSI2016-75313-R). In addition, A.J. González-Villar was
supported by a grant from the Portuguese Foundation for
Science and Technology within the scope of the Individual Call
for Stimulus to Scientific Employment 2017. N. Samartin-Veiga
was supported by a grant from the Spanish Government
(Ministerio de Economía y Competitividad; grant number BES2017-082684).

Publicação

Ano de Publicação: 2022

Editora: International Association for the Study of Pain

Identificadores

ISSN: 0304-3959